Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix Hexa infant immunogenicity study with MenC vaccine randomization
2012-003026-25Phase 4Completed
- Sponsor
- Health Protection Agency
- Start
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pertussis filamentous haemagglutinin, pneumococcal 13-valent conjugate vaccine, Meningococcal group C polysaccharide conjugate vaccine and Hib-MenC-TT in Preventable infectious diseases (VPD) (3 arms), sponsored by Health Protection Agency. Primary endpoints: Primary immune response based on accepted correlates of protection and Booster immune response. Started Aug 2012; status: completed.
02
Drugs
pertussis filamentous haemagglutininpneumococcal 13-valent conjugate vaccineMeningococcal group C polysaccharide conjugate vaccineHib-MenC-TT
03
Conditions
Preventable infectious diseases (VPD)
Beyond the preview
Go deeper on 2012-003026-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003026-25.